New approach offers non-surgical treatment option for BCC patients

Zynext Ventures USA LLC, the venture capital arm of Zydus Lifesciences, based in Ahmedabad, has invested in Feldan Therapeutics, an early clinical-stage pharmaceutical company from Canada that is leading the development of an intracellular delivery based treatments.

Feldan's proprietary Shuttle peptide technology allows for absolutely efficient and targeted delivery of biomolecules into the cell, providing therapeutic opportunities not imagined before.

Feldan's lead candidate FLD-103, is delivered intra-lesionally into basal cell carcinoma (BCC) lesions. The Shuttle peptide enables the delivery of a Hedgehog inhibitor to its target and ultimately, to resolve BCC within a particular cell.

The goal is to give patients with BCC a non-surgical option which improves the patient's outcome and ultimately quality of life.

Feldan is also working on a pulmonary programme to deliver therapeutic molecules into hard to reach lung cells via the Shuttle's distinct ability to deliver biomolecules, and to address the unmet, and rapidly growing medical needs of patients with respiratory disease.

Jay Kothari, Director of Zynext Ventures, highlighted, "Feldan's platform has the potential to transform intracellular delivery and pioneer next-generation therapeutics, aligning with the disruptive innovations we aim to add to our portfolio."